The 17 World’s Biggest Pharmaceutical Companies in 2024
The 17 World’s Biggest Pharmaceutical Companies–There are 17
World’s Biggest Pharmaceutical Companies in 2024 and this data is obtained
from the Annual reports of each company in 2024. Commonly, pharmaceutical
companies or drug companies are commercial companies that focus on researching,
developing, and distributing drugs, especially in terms of health problems.
They can manufacture generic drugs, branded drugs, medical devices, health
supplements, and various health products.
In terms of health, many of us as humans still depend on these
companies. Of course, of all the pharmaceutical companies scattered around the
world, only a few companies are able to become the leader of the world’s drug
and supplement business with the various brands that exist today. Here are the
17 World’s Biggest Pharmaceutical Companies Based on Annual Report Data for
each company in 2024. This ranking
order is based on the amount of profit/ net income obtained by each company in
2024.
Ranking Table of 17 World’s Biggest Pharmaceutical Companies in 2024 Based on Net Income
|
Rank |
Name of Pharmaceutical Companies |
Total Revenue |
Total Revenue |
Net Income |
Net Income |
|
Origin Currency |
in US Dollar (USD) |
Origin Currency |
in US Dollar (USD) |
||
|
1 |
Novo Nordisk |
DKK 290 billion |
USD 43.5 billion |
DKK 100 billion |
USD 15 billion |
|
2 |
Johnson & Johnson |
USD 88.8 billion |
USD 88.8 billion |
USD 14 billion |
USD 14 billion |
|
3 |
Abbott Laboratories |
USD 41.9 billion |
USD 41.9 billion |
USD 13.4 billion |
USD 13.4 billion |
|
4 |
Novartis |
USD 50.3 billion |
USD 50.3 billion |
USD 11.9 billion |
USD 11.9 billion |
|
5 |
Hoffman-La Roche |
CHF 62.3 billion |
USD 76 billion |
CHF 9.1 billion |
USD 11.1 billion |
|
6 |
Eli Lilly |
USD 45 billion |
USD 45 billion |
USD 10.5 billion |
USD 10.5 billion |
|
7 |
Pfizer |
USD 63.2 billion |
USD 63.2 billion |
USD 8 billion |
USD 8 billion |
|
8 |
Astrazeneca |
USD 54 billion |
USD 54 billion |
USD 7 billion |
USD 7 billion |
|
9 |
Sanofi |
EUR 41 billion |
USD 45.5 billion |
EUR 5.6 billion |
USD 6.2 billion |
|
10 |
AbbVie |
USD 56.3 billion |
USD 56.3 billion |
USD 4.28 billion |
USD 4.28 billion |
|
11 |
Amgen Inc |
USD 33.4 billion |
USD 33.4 billion |
USD 4 billion |
USD 4 billion |
|
12 |
GlaxoSmithKline |
GBP 31.3 billion |
USD 42.2 billion |
GBP 2.9 billion |
USD 3.9 billion |
|
13 |
Merck & co |
USD 21.1 billion |
USD 21.1 billion |
USD 2.7 billion |
USD 2.7 billion |
|
14 |
Takeda Pharmaceuticals |
JPY 4,581 billion |
USD 32 billion |
JPY 107 billion |
USD 0.75 billion |
|
15 |
Gilead Sciences |
USD 28.7 billion |
USD 28.7 billion |
USD 0.48 billion |
USD 0.48 billion |
|
16 |
Bayer |
EUR 46.6 billion |
USD 51.7 billion |
(EUR -2.5 billion) |
(USD -2.7 billion) |
|
17 |
Bristol Myers Squibb |
USD 48.3 billion |
USD 48.3 billion |
(USD -8.9 billion) |
(USD -8.9 billion) |
|
Source: Annual Report, 2024 |
|||||
|
Origin Currency: Currency that Officially Used in Annual
Report 2024 |
|||||
|
US Dollar Currency: Converted Currency from Origin
Currency to US Dollar |
|||||
|
Currency Rate: |
|||||
|
1 Swiss Franc (CHF) = 1.22 US Dollar (USD) |
|||||
|
1 Euro= 1.11 US Dollar (USD) |
|||||
|
1 Poundsterling (GBP) = 1.35 US Dollar (USD) |
|||||
|
1 Danish Krone (DKK) = 0.15 US Dollar (USD) |
|||||
|
1 Japanese Yen (JPY) = 0.0070 US Dollar (USD) |
|||||
In addition to the income and profit performance
obtained by each company, there is also a description related to the condition
of the company’s total assets and total liabilities obtained from the company’s
balance sheet of each company. The following is a description of the company’s
assets and debts. Additional data related to the condition of assets and debts
of the 17 world’s largest pharmaceutical companies in 2024.
Table of Total Assets and Liabilities of 17 World’s Biggest Pharmaceutical Companies in 2024
|
Rank |
Name of Pharmaceutical Companies |
Total Assets |
Total Assets |
Total Liabilities |
Total Liabilities |
|
Origin Currency |
in US Dollar (USD) |
Origin Currency |
in US Dollar (USD) |
||
|
1 |
Pfizer |
USD
213.3 billion |
USD
213.3 billion |
USD
124.8 billion |
USD
124.8 billion |
|
2 |
Johnson & Johnson |
USD
180.1 billion |
USD
180.1 billion |
USD
108.6 billion |
USD
108.6 billion |
|
3 |
Sanofi |
EUR
132.7 billion |
USD
147.2 billion |
EUR
54.8 billion |
USD
60.8 billion |
|
4 |
AbbVie |
USD
135.1 billion |
USD
135.1 billion |
USD
131.7 billion |
USD
131.7 billion |
|
5 |
Hoffman-La Roche |
CHF
101.8 billion |
USD
124.1 billion |
CHF
65.6 billion |
USD
80 billion |
|
6 |
Bayer |
EUR 110.8 billion |
USD 123 billion |
EUR 78.7 billion |
USD 87.3 billion |
|
7 |
Astrazeneca |
USD
104 billion |
USD
104 billion |
USD
63.1 billion |
USD
63.1 billion |
|
8 |
Novartis |
USD
102.2 billion |
USD
102.2 billion |
USD
58.1 billion |
USD
58.1 billion |
|
9 |
Takeda
Pharmaceuticals |
JPY
14,248 billion |
USD
99.7 billion |
JPY
7,312 billion |
USD
55.1 billion |
|
10 |
Bristol Myers Squibb |
USD
92.6 billion |
USD
92.6 billion |
USD
76.2 billion |
USD
76.2 billion |
|
11 |
Amgen Inc |
USD
91.8 billion |
USD
91.8 billion |
USD
85.9 billion |
USD
85.9 billion |
|
12 |
Abbott Laboratories |
USD
81.4 billion |
USD
81.4 billion |
USD
33.5 billion |
USD
33.5 billion |
|
13 |
GlaxoSmithKline |
GBP
59.4 billion |
USD
80.2 billion |
GBP
46.3 billion |
USD
62.5 billion |
|
14 |
Eli Lilly |
USD
78.7 billion |
USD
78.7 billion |
USD
64.4 billion |
USD
64.4 billion |
|
15 |
Novo Nordisk |
DKK
465 billion |
USD
69.7 billion |
DKK
322 billion |
USD
48.3 billion |
|
16 |
Gilead Sciences |
USD 58.9 billion |
USD 58.9 billion |
USD 39.7 billion |
USD 39.7 billion |
|
17 |
Merk & co |
USD
51.5 billion |
USD
51.5 billion |
USD
21.5 billion |
USD
21.5 billion |
|
Source: Annual
Report, 2024 |
|||||
|
Origin Currency:
Currency that Officially Used in Annual Report 2024 |
|||||
|
US Dollar Currency:
Converted Currency from Origin Currency to US Dollar |
|||||
|
Currency Rate: |
|||||
|
1 Swiss Franc (CHF) =
1.22 US Dollar (USD) |
|||||
|
1 Euro= 1.11 US
Dollar (USD) |
|||||
|
1 Poundsterling (GBP)
= 1.35 US Dollar (USD) |
|||||
|
1 Danish Krone (DKK) = 0.15 US Dollar (USD) |
|||||
|
1 Japanese Yen (JPY) = 0.0070 US Dollar (USD) |
|||||
Brief Description of 17 World’s Biggest Pharmaceutical Companies in 2024
1. Hoffman-La Roche
Founded in 1896 by Fritz Hoffmann-La Roche, F. Hoffmann-La Roche
AG is the world’s biggest pharmaceutical company in 2020. This company has a main office in Bassel,
Switzerland. Initially, the company produced a variety of multivitamin products
and in 1934, it became the first to mass-produce synthetic vitamin C, under the
brand name Redoxon but it has been owned by Bayer. Specifically, Hoffman-La Roche focussed on Pharmaceuticals and Diagnostics activities, Roche Pharmaceuticals focused
on finding new medicines and diagnostics that help patients live longer, better
lives and evolve the practice of medicine. Meanwhile, Roche Diagnostics provides tools that prevent diseases
from being diagnosed and monitored.
Commonly, as one of the world’s biggest pharmaceutical companies, Roche has some top-selling pharmaceuticals products , namely Ocrevus (Neurology), Hemlibra (Haemophilia A), Perjeta (Oncology), Tecentriq (Oncology), Actemra/RoActemra (Immunology), Vabysmo (Ophthalmology), Xolair (Immunology), Kadcyla (Oncology), MabThera/Rituxan (Oncology/Immunology), and Herceptin (Oncology) with total selling around CHF 6.3 billion, CHF 4.1 billion, CHF 3.7 billion, CHF 3.7 billion, CHF 2.6 billion, CHF 2.3 billion, CHF 2.1 billion, CHF 1.9 billion, CHF 1.63 billion, and CHF 1.62 billion, respectively.
Financially, during 2024, the Hoffman-La Roche earned revenues of CHF 62.3 billion or equivalent
to USD 76 billion with a net income of CHF 9.1 billion or equivalent to USD
11.1 billion. In terms of financial position, according to its balance sheet, Hoffman-La Roche has total assets of USD 213.3 billion with total
liabilities of around USD 124.8 billion.
2. Johnson & Johnson
Johnson & Johnson (J&J) is one the world’s biggest pharmaceutical
companies in 2023 from the United States. Historically, this company was
founded in 1886 in New Brunswick, New Jersey, the United States of America by Robert Wood Johnson, James Wood Johnson,
and Edward Mead Johnson. Along with the development of time and business progression, many
healthcare products produced by this company have been marketed in various parts of the world.
As of 2023, the company’s operations include approximately 250
subsidiaries operating in 60 countries with products sold in more than 175
countries and have approximately 131,900 employees worldwide engaged in the
research and development, manufacture and sale of a broad range of products in
the healthcare field. Operationally, Johnson&Johnson is now organized into
two business segments, namely Innovative Medicine and MedTech.
In addition, in medicine segments, Johnson&Johnson has the
Company’s key pharmaceutical products, namely STELARA (ustekinumab) accounted
for approximately 12.8% of the Company’s total revenues for fiscal year of
2023, followed by DARZALEX (daratumumab) and DARZALEX FASPRO (daratumumab and
hyaluronidase-fihj), accounted for approximately 11.4% of the Company’s total
revenues in 2023. In addition, a variety of healthcare products produced by
Johnson-Johnson such as Clean and Clear, Listerine, Johnson Baby Powder,
Mylanta, Visine eye drops. Regarding the Covid pandemic, this company is one of
the producers and makers of the Covid-19 vaccine.
Financially in 2024, according to its annual
report, Johnson&Johnson successfully earned total revenues of USD
88.8 billion with a net income of USD 14 billion. In terms of financial
position, total assets of Johnson &
Johnson USD 180.1 billion and total liabilities reaching USD 108.6
billion.
3. Sanofi
Founded in 1973, Sanofi S.A is one of the world’s biggest
pharmaceutical companies in the world by 2023. This company has its main office
in Paris, France. In 2004, Sanofi-Synthélabo merged with Aventis and changed
its name to Sanofi-Aventis. However, the company later changed its name back to
Sanofi in May 2011. Some of Sanofi’s medicinal products include platogrix,
Amaryl, Lantus Solostar, and Toplexil. Commonly, sanofi has engaged in
research and development, manufacturing, and marketing of pharmacological
products, focussing in Immunology Research and development (R&D), Neurology
R&D, Oncology R&D, Rare Blood Disorders R&D, Rare Diseases R&D
and Vaccines R&D.
Financially, in 2024, this
Sanofi successfully earned total revenues of EUR 41 billion or equivalent to USD 45.5 billion and successfully gained a net income of EUR 5.6 billion or equivalent to
USD 6.2 billion.
4. Pfizer
Pfizer Inc. is an American multinational pharmaceutical and
biotechnology company headquartered in Manhattan, New York City. Founded in
1849 in New York City by Charles
Pfizer and Charles F. Erhart, the company has grown rapidly to become one
of the biggest pharmaceutical companies in the world. In 2024, Pfizer successfully earned total revenues of USD 63.2 billion and successfully gained a net income of USD 8 billion. In terms of financial position in 2024, Pfizer
has total assets of around USD 213.3 billion and total liabilities of around
USD 124.8 billion.
Commonly, some of the famous products from Pfizer are Viagra (one
of the phenomenal ones), Lipitor, Combantrin worm medicine. In relation to the
impact of the COVID-19 pandemic, this company has also issued a Covid-19
vaccine and has been distributed in various countries around the world.
Along with business development, Pfizer has ten manufacturing
sites and two distribution centers in Andover (MA), Franklin (OH), Kalamazoo
(MI), MCPherson (KS), Middleton (WI), Pearl River (NY), Rochester (MI), Rocky
Mount (NC), and Sanford (NC). In addition, Some of the Pfizer
products include Oncology, Primary care, and
specialty care. Oncology (Ibrance, Xtandi, Inlyta, Bosulif, Lorbrena, Braftovi,
Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio and Tivdak). Meanwhile,
Primary Care including Internal medicine (Eliquis, the Premarin family and
BMP2), Migraine (Nurtec ODT/Vydura and Zavzpret), Vaccines (Comirnaty, the
Prevnar family, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix and Trumenba), Treatment
for COVID-19 (Paxlovid), Detection of COVID-19 and influenza (Lucira by
Pfizer). In addition, Specialty Care including Inflammation & immunology
(Xeljanz, Enbrel (outside the U.S. and Canada), Inflectra, Cibinqo, Litfulo and
Velsipity), Rare disease (the Vyndaqel family, Genotropin, BeneFIX, Oxbryta,
Somavert and Ngenla), Hospital (Sulperazon, Zavicefta, Zithromax, Medrol and
Panzyga).
5.GlaxoSmithKline
GlaxoSmithKline plc (GSK) is one of the world’s biggest
pharmaceutical companies originating in the UK. The company’s head office is in
London, England. Founded in 2000, through the merger of Glaxo Wellcome and SmithKline Beecham, the company has grown
rapidly and has become one of the biggest pharmaceutical companies in the world
alongside Pfizer, Novartis, Roche, Sanofi, and Merck & Co.
Some of the products sold, namely Sensodyne toothpaste, and the
headache reliever Panadol are some of the other products. As of 2024, GlaxoSmithKline
(GSK) has Commercial operations in manufacturing Specialty Medicines, General
Medicine, and Vaccines. Specifically, Specialty Medicines of
GlaxoSmithKline’s products are Dovato (HIV treatment), Nucala (Respiratory
eosinophil-driven diseases), Triumeq (HIV treatment), Tivicay (HIV treatment),
Benlysta (Lupus and lupus nephritis), Cabenuva (HIV treatment), Juluca (HIV
treatment), Zejula (Ovarian cancer), Jemperli (Endometrial cancer),
Rukobia (HIV treatment), Xevudy (COVID-19 treatment), Blenrep (Blood cancer –
multiple myeloma), Ojjaara/Omjjara (Myelofibrosis), and Jesduvroq/Duvroq
Anaemia due to chronic kidney disease (CKD). In addition, the General
Medicine of GlaxoSmithKline (GSK) includes Trelegy Ellipta (COPD, asthma),
Seretide/Advair (Asthma, COPD), Relvar/Breo Ellipta (Asthma, COPD), Ventolin
(Asthma, COPD),Augmentin (Common bacterial infections), Anoro Ellipta (COPD),
Avodart & Duodart (Benign prostatic hyperplasia (BPH), Avamys/Veramyst
(Allergic rhinitis), and Dermovate, Betnovate, Cutivate, Eumovate (Inflammatory
skin conditions).
Furthermore, the vaccines produced by GlaxoSmithKline (GSK) are
Shingrix (Herpes zoster (shingles)), Arexvy (RSV), Bexsero (Meningitis group
B), Boostrix (Diphtheria, tetanus, acellular pertussis booster), Rotarix
(Rotavirus), Fluarix, FluLaval (Seasonal influenza), Infanrix, Pediarix
(Diphtheria, tetanus, pertussis, polio, hepatitis B, haemophilus influenza type
B), Engerix, Twinrix, Havrix (Hepatitis), Menveo (Meningitis group A, C, W and
Y), Synflorix (Invasive disease, pneumonia, acute otitis media), Priorix,
Priorix Tetra, Varilrix (Measles, mumps, rubella and chickenpox), and Cervarix
(Human papillomavirus).
In 2024, based on the company’s 2024 annual report, the
GlaxoSmithKline successfully earned total revenue of GBP 31.3 billion or
equivalent to USD 42.2 billion, with a net income of GBP 2.9 billion or
equivalent to USD 3.9 billion. In terms of financial position, GlaxoSmithKline
has total assets of around GBP 59.4 billion or equivalent to USD 80.2 billion
with total liabilities of GBP 46.3 billion or equivalent to USD 62.5 billion.
6. Novartis
Novartis International AG is a Swiss multinational pharmaceutical
company based in Basel, Switzerland and Novartis has employed 76,057 of
employees as of December 31, 2023. This company is one of the largest
pharmaceutical companies in the world which was founded in December 2000 in
London, England. Along with business development, Sanovi has sold its medicine products in approximately
130 countries around the world. Basically, some of the novartis’s
medicines products in treating different treatments ,namely Cardiovascular,
renal and metabolic ( Entresto, Leqvio (inclisiran), Immunology (Cosentyx
(secukinumab), Xolair (omalizumab), Ilaris (canakinumab)), Neuroscience
(Kesimpta (ofatumumab), Zolgensma (onasemnogene abeparvovec)), Oncology
(Promacta/Revolade (eltrombopag), Kisqali (ribociclib), Tafinlar + Mekinist
(dabrafenib + trametinib), Tasigna (nilotinib), Jakavi (ruxolitinib), Pluvicto
(lutetium (177Lu) vipivotide tetraxetan), Lutathera (lutetium Lu 177
dotatate/lutetium (177Lu) oxodotreotide)).
Financially, in 2024, according to its annual report, Novartis
International successfully earned total revenues of USD 50.3 billion with a
net net income that reached USD 11.9 billion. In terms of financial position, Novartis International has total assets of
around USD 102.2 billion and total liabilities of around USD 58.1 billion.
7. Merck & co
Merck & Co., Inc. or Merck Sharp & Dohme (MSD) is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. The founders of this company are Theodore Weicker and George Merck.
In pharmaceutical industries, Merck & Co., Inc has some
popular medicine products. These are Keytruda with sales of $ 25 billion in
2023, Gardasil/Gardasil 9 ($ 8.8 billion), Januvia/Janumet ($ 3.3 billion),
ProQuad/M-M-R II/Varivax ($ 2.3 billion), Bridion ($ 1.8 billion),
Lagevrio ( $ 1.4 billion), Lynparza ( $1.1 billion), Lenvima ($ 960 million),
RotaTeq ($ 769 million), and Vaxneuvance ($ 665 million).
Financially, in 2024, this Merck & Co successfully earned
total revenues of USD 21.1 billion with a net income that reached USD 2.7
billion. In terms of financial position, the total assets of Merck & Co
reached USD 51.5 billion and total liabilities of around USD 21.5 billion.
8. AbbVie
AbbVie is a pharmaceutical company that has its main office in
North Chicago, Illinois, the United States of America which was founded in
2013. Actually, Abbvie was formed due to the divestment of Abbott Laboratories which used to
be one with Abbott Laboratories.
Commonly, AbbVie has some different medicinal products for
different diseases and cases. These AbbVie’s portfolio of products includes
Immunology products (Humira (adalimumab), Skyrizi (risankizumab)), Oncology
products (Imbruvica (ibruti nib), Venclexta (venetoclax), Epkinly (epcoriti
mab), Elahere (mirvetuximab soravtansine-gynx)), Aesthetics products ( Botox
Cosmetic, The Juvederm Collection of Fillers),
Neuroscience products( Botox Therapeutic, Vraylar (cariprazine), Duopa and
Duodopa (carbidopa and levodopa), Ubrelvy (ubrogepant), Qulipta (atogepant)),
Eye care products (Ozurdex (dexamethasone intravitreal implant), Lumigan
(bimatoprost ophthalmic solution), Alphagan (brimonidine tartrate ophthalmic
solution), Restasis)) and other key products ( Mavyret
(glecaprevir/pibrentasvir), Creon (pancrelipase), Lupron (leuprolide acetate),
Linzess (linacloti de), Synthroid (levothyroxine sodium tablets, USP)).
Financially, in 2024, AbbVie successfully earned total revenues of
USD 56.3 billion with a net income of USD 4.28 billion. In terms of financial
position, AbbVie has total assets of USD 135.1 billion and total liabilities of around USD
131.7 billion.
9. Abbott Laboratories
Abbott Laboratories is a medical and healthcare equipment company
headquartered in Abbott Park, Illinois, United States. Based on its history,
this company was founded by a doctor named Wallace Calvin Abbott in 1888 and as of 2023, Abbot employed
114 thousand people.
Commonly, with more
than 135 years of experience, Abbot laboratories has some medicine products.
These are Creon, Duspatal and Dicetel, Heptral, Transmetil, and Samyr,
Duphalac, Duphaston, Femoston, Lipanthyl and TriCor, Teveten and Teveten Plus,
Physiotens, Synthroid, Serc, Brufen, Sevedol, Klacid, Claribid, Klaricid, and
Influvac.
Financially, according to the annual report in 2024, Abbott
Laboratories successfully earned total revenues of USD 41.9 billion with a net
profit of USD 13.4 billion. In terms of financial position, Abbott Laboratories
has total assets of around USD 81.4 billion and total liabilities of around USD
33.5 billion.
10.AstraZeneca
AstraZeneca plc is a British-Swedish multinational pharmaceutical
and biotechnology company headquartered at the Cambridge Biomedical Campus in
Cambridge, England. Perhaps, one of the most popular products is the
Oxford-AstraZeneca COVID-19 vaccine, which has been widely marketed in various
countries around the world. The foundation of this company was in 1999 through
the merger of Astra AB of Sweden and the Zeneca Group of the UK. Financially,
in 2024, this company earned total revenues of USD 54 billion with a net income
of USD 7 billion. In terms of financial position, total assets of AstraZeneca
around USD 104 billion and total liabilities of around USD 63.1 billion.
Commonly, AstraZeneca
focussed on Oncology and BioPharmaceuticals (including Cardiovascular, Renal
& Metabolism, and Respiratory & Immunology); and Rare Disease. On
Oncology, AstraZeneca has some medicine
products, namely Tagrisso (osimertinib), Imfinzi (durvalumab), Lynparza
(olaparib), Calquence (acalabrutinib), Enhertu (trastuzumab deruxtecan),
Orpathys (savolitinib), Truqap (capivasertib), Zoladex (goserelin acetate
implant), Faslodex (fulvestrant). Meanwhile in Cardiovascular, Renal &
Metabolism, AstraZeneca has some medicine
products, namely Farxiga/Forxiga (dapagliflozin), Brilinta/Brilique
(ticagrelor), Lokelma (sodium zirconium cyclosilicate), Roxadustat,
Andexxa/Ondexxya (andexanet alfa), Crestor (rosuvastatin calcium),
Seloken/Toprol-XL (metoprolol succinate), Onglyza family, (exenatide, Qtern,
Symlin, Atacand and other established brands), Bydureon (exenatide XR
injectable suspension).
In Respiratory & Immunology, AstraZeneca has medicine products i.e. Symbicort (budesonide/
formoterol), Fazenda (benralizumab),
Breztri/Trixeo (budesonide/ glycopyrrolate/ formoterol), Tezspire
(tezepelumab), Saphnelo (anifrolumab), Pulmicort (budesonide), Bevespi
(glycopyrrolate/formoterol), Daliresp/Daxas (roflumilast). Furthermore, in
Vaccines & Immune Therapies, the products of AstraZeneca are COVID-19 mAbs (tixagevimab and cilgavimab), Beyfortus
(nirsevimab), Vaxzevria (ChAdOx1-S [Recombinant]), Synagis (palivizumab),
Fluenz Tetra/FluMist Quadrivalent (live attenuated influenza vaccine). In
addition of Rare Disease, the products are Soliris (eculizumab), Ultomiris
(ravulizumab), Strensiq (asfotase alfa), Koselugo (selumetinib), Kanuma
(sebelipase alfa).
11. Bristol Myers Squibb
The Bristol Myers Squibb corporation was founded in 1858 by Edward
Robinson Squibb in Brooklyn, New York. Operationally, this company has
Headquartered in Princeton, New Jersey. To date Bristol Myers Squibb has
manufacturing operations in the U.S., Puerto Rico, Switzerland, Ireland, and
the Netherlands. Meanwhile, Some of the Bristol Myers Squibb products are
In-Line Products (Eliquis Eliquis (apixaban), Opdivo (nivolumab), Orencia
(abatacept), Pomalyst /ImnovidPomalyst/Imnovid (pomalidomide), Yervoy (ipilimumab), Sprycel (dasatinib)), New Product
Portfolio (Reblozyl (luspatercept-aamt),
Opdualag (nivolumab and relatlimab-rmbw), Abecma (idecabtagene vicleucel), Zeposia (ozanimod), Breyanzi (lisocabtagene
maraleucel), Camzyos (mavacamten).
In the year 2024, Bristol Myers Squibb had total assets of USD
92.6 billion with the liabilities around USD 76.2 billion. According to
business performance, Bristol Myers Squibb successfully generated revenue of
USD 48.3 billion but suffered net loss around USD -8.9 billion.
12. Takeda Pharmaceuticals
Historically, the journey of Takeda pharmaceutical was started in
1781 with the initiative
of Chobei Takeda who started a business selling traditional Japanese and
Chinese medicines in Doshomachi, Osaka. Along with business development, Takeda
pharmaceuticals have presence in approximately 80 countries, with leading
positions in Japan and the U.S and more than 25 manufacturing sites.
Operationally, Takeda Pharmaceuticals still
has its headquarters in Tokyo, Japan. Based on
the products, Some of the Takeda pharmaceuticals products are Entyvio,
Alofisel, TAKHZRO, Livtencity, Cuvitru, Flexbumin, Alunbrig, EXKIVITY, Qdenga,
spikevax, and others.
Financially in 2024, according to
a financial report, Tekeda Pharmaceuticals has total
assets of JPY 14,248 billion or equivalent with USD 99.7 billion. In Business
performance, Takeda generated total revenue of JPY 4,581 billion or equivalent
to USD 32 billion and successfully gained net
income of JPY 107 billion or equivalent to USD 0.75 billion.
13. Eli Lilly
Historically, Eli Lilly was founded by Colonel Eli Lilly in 1876 and has
headquartered in Indianapolis, Indiana. Based on products, some of the Eli Lilly products are Diabetes, Obesity and Other Cardiometabolic
(Basaglar, Humalog, Insulin Lispro, Humulin, Jardiance, Mounjaro, Trulicity),
Oncology products ( Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyr),
Immunology products (Ebglyss, Olumiant, Omvoh,
Taltz), Neuroscience (Cyambalta, Emgality).
Financially, according to its annual report in 2024, Eli Lilly has total assets around USD 78.7 billion with total liabilities of around USD 64.4 billion. In terms of business performance in 2024, Eli Lilly generated total revenue of USD 45 billion and gained net income of USD 10.5 billion.
14. Novo Nordisk
Novo Nordisk is a Danish multinational pharmaceutical company
which was founded on December 21st, 1923.
Operationally, this company has a main office
in Bagsværd, Denmark. As of 2023, Novo Nordisk employed more than 64 thousand
people with 5 R&D Facilities in 5 different countries.
As of business development, Novo Nordisk has some medicine
products in Obesity medications (Saxenda and Wegovy), Diabetes medications
(Tresiba, Xultophy,levemir, Insulatard, Actrapid, Mixtard, NovoMix, Ryzodeg,
Rybelsus, Victoza, Ozempic, Fiasp,Novorapid, GlucaGen) Haemophilia medications
(NovoSeven, NovoEight, Refixia, Esperoct) , Growth disorder medications
(Norditropin and Sogroya), Hormone replacement therapy (vagifem, Activelle,
Kliogest, Novofem, and others).
Financially, according to the Annual Report in 2024, Novo Nordisk
has total assets around DKK 465 billion or equivalent with USD 69.7 billion
with total liabilities of around DKK 322 billion or equivalent USD 48.3
billion. Based on performance in 2024, Novo Nordisk generated total revenue of
DKK 290 billion or equivalent to USD 43.5 billion and gained net income of DKK
100 billion or equivalent to USD 15 billion.
15. Amgen
Amgen is an American-based pharmaceutical company which was incorporated in
California in 1980 and became a Delaware corporation in 1987. As of business
development, Amgen has a presence in approximately 100 countries worldwide.
Commonly, Amgen has some medicine products including Prolia, ENBREL, Otezla
XGEVA, Repatha, Nplate, KYPROLIS, Aranesp, EVENITY, Vectibix, BLINCYTO,
TEPEZZA, KRYSTEXXA.
In the financial positions and business performance of 2024, Amgen
had total assets around USD 91.8 billion with total liabilities around USD 85.9
billion. According to business performance in 2024, Amgen successfully generated total revenue of USD
33.4 billion with net income around USD 4 billion.
16. Bayer
Bayer AG is a global pharmaceutical company founded by Friedrich
Bayer and Johann Friedrich Weskott in
August 1863. As of 2024, Bayer has employed 94,081
people. Along with business development,
in the pharmaceutical products, Bayer AG has Bayer AG has research and
development sites in Berlin (Germany), Whippany (United States), Wuppertal
(Germany) and production sites of its pharmaceutical products located in
Bergkamen (Germany), Berlin (Germany), and Leverkusen (Germany). Furthermore, some of well-known pharmaceutical brands
from Bayer are Xarelto™, Eylea™, Nubeqa™, Mirena™/Kyleena™/Jaydess™, Adempas™,
Kogenate™/Kovaltry™/Jivi™, YAZ™/Yasmin™/Yasminelle™, Aspirin™ Cardio, CT Fluid
Delivery, Ultravist™, Adalat™, Kerendia™, Stivarga™, Gadovist™ product family,
Betaferon™/Betaseron™.
Financially, in 2024, according to the annual report of 2024,
Bayer AG has total assets of around EUR 110.8 billion or equivalent to USD 123
billion with total liabilities of around EUR 78.7 billion or equivalent to USD
87.3 billion. In terms of business performance in 2024, Bayer AG successfully
gained total revenue of EUR 46.6 billion or equivalent to USD 51.7 billion but
suffered net loss of around EUR -2.5 billion or equivalent to USD -2.7 billion.
17. Gilead Sciences
Gilead Sciences, Inc is an American biopharmaceutical company
headquartered in Foster City, California originally founded by Michael L.
Riordan. Gilead has operated in 35 countries worldwide and provided medicines
to prevent and treat life-threatening diseases, including HIV, viral hepatitis,
coronavirus disease (“COVID-19”), cancer and inflammation. Furthermore, some of
medicinal brands from Gilead sciences are HIV treatment (Biktarvy, Genvoya,
Descovy, Odefsey, Complera /Eviplera, Symtuza, Truvada, Stribild), Liver
Disease treatment (Epclusa, Vemlidy, Harvoni, Viread, Livdelzi (seladelpar)),
COVID-19 (Veklury (remdesivir)), Cell Therapy treatment (Yescarta (axicabtagene
ciloleucel), Tecartus (brexucabtagene autoleucel).
Financially, according to the annual report of 2024, Gilead Sciences has total assets of around USD 58.9 billion with total liabilities of around USD 39.7 billion. Furthermore, in terms of business performance in 2024, Gilead Sciences successfully gained total revenue of around USD 28.7 billion and net income of around USD 0.48 billion.
The Summary of 17 World’s Biggest Pharmaceutical Companies Based on Total Assets in 2024
The Summary of 17 World’s Biggest Pharmaceutical Companies Based on Net Income in 2024
Bibliography of 17 world’s Biggest Pharmaceutical Companies in 2024
Novo Nordisk. 2025. Annual Report 2024. Accessed via https://www.novonordisk.com/investors/annual-report.html
on June 1st, 2025.
Johnson& Johnson. 2025. Annual Report 2024. Accessed via
https://www.jnj.com/corporate-reports on June 1st, 2025.
Abbott Laboratories. 2025. Annual Report 2024. Accessed via https://www.abbottinvestor.com/financials/annual-reports/
on June 1st, 2025.
Novartis. 2025. Annual Report 2024. Accessed via https://www.novartis.com/investors/financial-data/annual-results
on June 1st, 2025.
Hoffman-La Roche. 2025. Annual Report 2024. Accessed via https://www.roche.com/investors/annualreport24
on June 1st, 2025.
Eli Lily. 2025. Annual Report 2024. Accessed via https://investor.lilly.com/financial-information/annual-reports
on June 1st, 2025.
Pfizer. 2025. Annual Report 2024. Accessed via https://investors.pfizer.com/Investors/Financials/Annual-Reports/default.aspx
on June 1st, 2025.
Astrazeneca. 2025. Annual Report 2024. Accessed via https://www.astrazeneca.com/investor-relations/annual-reports/annual-report-2024.html
on June 1st, 2025.
Sanofi. 2025. Annual Report 2024. Accessed via https://www.sanofi.com/en/india/consumer-healthcare/investors/annual-reports
on June 1st, 2025.
AbbVie. 2025. Annual Report 2024. Accessed via https://investors.abbvie.com/news-releases/news-release-details/abbvie-reports-full-year-and-fourth-quarter-2024-financial
on June 1st, 2025.
Amgen Inc. 2025. Annual Report 2024. Accessed via https://investors.amgen.com/financials/annual-reports
on June 1st, 2025.
GlaxoSmithKline. 2025. Annual Report 2024. Accessed via https://www.gsk.com/en-gb/investors/financial-reports/annual-report-2024/ on June 1st, 2025.
Merck & co. 2025. Annual Report 2024. Accessed via https://www.merckgroup.com/en/annualreport/2024/ on June 1st, 2025.
Takeda Pharmaceuticals. 2025. Annual Report 2024. Accessed
via https://www.takeda.com/investors/annual-integrated-report/ on June 1st, 2025.
Gilead Sciences. 2025. Annual Report 2024. Accessed via https://investors.gilead.com/overview/default.aspx on June 1st, 2025.
Bayer. 2025. Annual Report 2024. Accessed via https://www.bayer.com/en/investors/integrated-annual-reports
on June 1st, 2025.
Bristol Myers Squibb. 2025. Annual Report 2024. Accessed via
https://annual-report.bms.com/
on June 1st, 2025.